Navigation Links
Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
Date:2/6/2008

CAMBRIDGE, Mass., Feb. 6 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview at the upcoming BIO CEO & Investor Conference on Tuesday, February 12, 2008 at 9:30 a.m. ET in the Park Avenue Suite Center/North Room at the Waldorf-Astoria Hotel in New York, NY.

The live and archived webcasts of the presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at http://www.idenix.com or directly linking to http://phx.corporate-ir.net/phoenix.zhtml?p=irol- eventDetails&c=131556&eventID=1752370. (Due to the length of URL, please cut and paste into browser). Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived replay will be available on the Idenix website for two weeks following the conference.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals' Contacts:

Media: Teri Dahlman (617) 995-9905

Investors: Amy Sullivan (617) 995-9838


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... ... soon resume cervical and lumbar disc production, company President, Jake Lubinski will be ... are implanting the AxioMed disc in Cologne and Karlsruhe to discuss the benefits ...
(Date:12/5/2016)...  Renova™ Therapeutics, a biotechnology company developing gene ... chronic diseases, announced that Catherine Bovenizer , ... Officer (CFO), effective today. Ms. Bovenizer ... in financial management for a variety of public ... recently, Ms. Bovenizer was the Vice President of ...
(Date:12/5/2016)... GRAND RAPIDS, Mich. , Dec. 5, 2016 NxGen MDx ... "By bringing the test in house, we,ve been able to improve ... costs down for patients," says Alan Mack , CEO of NxGen ... , , ... increase in test volume has led to more job opportunities at the ...
(Date:12/5/2016)... DUBLIN , Dec 5, 2016 ... new report "DNA Sequencing - Technologies, Markets and Companies" ... ... This report briefly reviews basics of human genome variations, development ... sequencers are described as well as companies developing them. Various ...
Breaking Biology Technology:
(Date:11/16/2016)... Nov. 16, 2016 Sensory Inc ., ... security for consumer electronics, and VeriTran , ... retail industry, today announced a global partnership that ... to authenticate users of mobile banking and mobile ... software which requires no specialized biometric scanners, ...
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
Breaking Biology News(10 mins):